US News

Sanofi-GSK report positive interim results for their COVID-19 shot

Published by
Reuters

By Matthias Blamont PARIS (Reuters) – An experimental COVID-19 vaccine developed by Sanofi and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling them to move to a late-stage study, the French drugmaker said on Monday. Sanofi and Britain’s GSK said a global Phase III trial would start in the coming weeks and involve more than 35,000 adults, with the hope of seeing the vaccine approved by the fourth quarter after having initially targeted the first half of this year before a setback. Sanofi and GSK last December were forced to restart their trial whe…

Read More

Facebook Comments

Check Also

Global COVID-19 cases surpass 200 million as Delta variant spreads

Published by Reuters By Roshan Abraham and Kavya ...

Archives